News | May 07, 2026
CARBOGEN AMCIS Shanghai site clears unannounced NMPA GMP inspection
Successful inspection outcome strengthens company’s regulatory compliance and manufacturing standards in China
Successful inspection outcome strengthens company’s regulatory compliance and manufacturing standards in China
The Puducherry facility, dedicated to Ibuprofen and its derivatives, is equipped with advanced infrastructure to serve both domestic and international markets
Patalganga plant received zero observation from USFDA earlier
Platform integrates VR simulations and AI-driven coaching to build job-ready skills in pharma manufacturing
Bulling brings extensive experience across the biopharma and CDMO landscape, with leadership roles spanning both drug substance and drug product operations
By prioritising absolute compliance, leveraging the power of digital tools, and aligning with government policies, the sector is locking in its future leadership
PMDA is regarded among the most stringent regulatory bodies globally
The inspection is now closed, and no regulatory action has been recommended
The inspection concluded with zero observations, confirming the facility's compliance with current Good Manufacturing Practices
Operational leverage kicked in during the quarter, with adjusted EBITDA rising 21% year-on-year to Rs 147 crore
Subscribe To Our Newsletter & Stay Updated
